Müllerian inhibiting substance regulates its receptor/SMAD signaling and causes mesenchymal transition of the coelomic epithelial cells early in Müllerian duct regression
Open Access
- 15 June 2006
- journal article
- Published by The Company of Biologists in Development
- Vol. 133 (12), 2359-2369
- https://doi.org/10.1242/dev.02383
Abstract
Examination of Müllerian inhibiting substance (MIS) signaling in the rat in vivo and in vitro revealed novel developmental stage- and tissue-specific events that contributed to a window of MIS responsiveness in Müllerian duct regression. The MIS type II receptor (MISRII)-expressing cells are initially present in the coelomic epithelium of both male and female urogenital ridges, and then migrate into the mesenchyme surrounding the male Müllerian duct under the influence of MIS. Expression of the genes encoding MIS type I receptors, Alk2 and Alk3, is also spatiotemporally controlled; Alk2 expression appears earlier and increases predominantly in the coelomic epithelium, whereas Alk3 expression appears later and is restricted to the mesenchyme, suggesting sequential roles in Müllerian duct regression. MIS induces expression of Alk2, Alk3 and Smad8, but downregulates Smad5 in the urogenital ridge. Alk2-specific small interfering RNA (siRNA) blocks both the transition of MISRII expression from the coelomic epithelium to the mesenchyme and Müllerian duct regression in organ culture. Müllerian duct regression can also be inhibited or accelerated by siRNA targeting Smad8 and Smad5, respectively. Thus, the early action of MIS is to initiate an epithelial-to-mesenchymal transition of MISRII-expressing cells and to specify the components of the receptor/SMAD signaling pathway by differentially regulating their expression.Keywords
This publication has 65 references indexed in Scilit:
- Conditional deletion of β-catenin in the mesenchyme of the developing mouse uterus results in a switch to adipogenesis in the myometriumDevelopmental Biology, 2005
- Activin receptor-like kinase 2 and Smad6 regulate epithelial–mesenchymal transformation during cardiac valve formationDevelopmental Biology, 2005
- Genetic studies of the AMH/MIS signaling pathway for Müllerian duct regressionMolecular and Cellular Endocrinology, 2003
- Fibronectin requirement in branching morphogenesisNature, 2003
- Transduction pathway of anti-Müllerian hormone, a sex-specific member of the TGF-β familyTrends in Endocrinology & Metabolism, 2003
- Requirement of Bmpr1a for Müllerian duct regression during male sexual developmentNature Genetics, 2002
- Mullerian Inhibiting Substance Signaling Uses a Bone Morphogenetic Protein (BMP)-Like Pathway Mediated by ALK2 and Induces Smad6 ExpressionMolecular Endocrinology, 2001
- Persistence of müllerian derivatives in malesAmerican Journal of Medical Genetics, 1999
- Effect of human recombinant mullerian inhibiting substance on isolated epithelial and mesenchymal cells during mullerian duct regression in the ratEndocrinology, 1992
- The epithelial-mesenchymal interface of the male rat Mullerian duct: Loss of basement membrane integrity and ductal regressionDevelopmental Biology, 1982